Increased plasma monocyte chemoattractant protein-1 levels in patients with isolated low high-density lipoprotein cholesterol

References

• Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008;23:370–8.
   PubMed Web of Science ®Google Scholar
• Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 2008;15:52–62.
   PubMed Web of Science ®Google Scholar
• Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124:S11–20.
   PubMed Web of Science ®Google Scholar
• Brewer HB Jr, Santamarina-Fojo S. Clinical significance of high- density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter. Am J Cardiol 2003;92:10K–6K.
   PubMed Web of Science ®Google Scholar
• Acharjee S, Boden WE, Hartigan PM, Teo KK, Maron DJ, Sedlis SP, Kostuk W, Spertus JA, Dada M, Chaitman BR, Mancini GB, Weintraub WS. Low levels of high density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post hoc analysis from the COURAGE trial. J Am Coll Cardiol 2013;62:1826–33.
   PubMed Web of Science ®Google Scholar
• Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7:678–89
   PubMed Web of Science ®Google Scholar
• Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000;18:217–42.
   PubMed Web of Science ®Google Scholar
• Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610–21.
   PubMed Web of Science ®Google Scholar
• Bursill CA, Channon KM, Greaves DR. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol 2004;15:145–9.
   PubMed Web of Science ®Google Scholar
• Boisvert WA. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med 2004;14:161–5.
   PubMed Web of Science ®Google Scholar
• Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88:1121–7.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP, Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003;107:690–5.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS, Califf RM, Braunwald E. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 2007;50:2117–24.
   PubMed Web of Science ®Google Scholar
• Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995;15:1987–94.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, Rye KA, Barter PJ. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005;111;1543–50.
   PubMed Web of Science ®Google Scholar
• Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP, Remaley AT, Sviridov D, Chin-Dusting J. High density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008;28:2071–7.
   PubMed Web of Science ®Google Scholar
• Tolle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowsk S, Keul P, Assmann G, Chun J, Levkau B, Van der Giet M, Nofer JR. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008;28:1542–8.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135–43.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709–16.
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PW. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994;35:871–8.
   PubMed Web of Science ®Google Scholar
• Mahley RW, Bersot TP. Low levels of high-density lipoproteins in the Turkish population: a risk factor for coronary heart disease. Türk Kardiyol Dern Arş 1999; 27: 37–43.
   Google Scholar
• Mahley RW, Bersot TP. Genetics determinants of low HDL; insight from studies of the Turkish population. Atherosclerosis 1999;146:S8.
   Web of Science ®Google Scholar
• Onat A, Hergenç G, Uzunlar B. HDL-cholesterol as a coronary risk factors in Turkish society: its predictor, determines and relations. Türk Kardiyol Dern Arş 2003;31:9–16.
   Google Scholar
• Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004;95:764–72.
   PubMed Web of Science ®Google Scholar
• Varol E, Bas HA, Aksoy F, Ari H, Ozaydin M. Relationship between neutrophil-lymphocyte ratio and isolated low high-density lipoprotein cholesterol. Angiology 2013;65:630–3.
   PubMed Web of Science ®Google Scholar
• Karabacak M, Varol E, Kahraman F, Ozaydin M, Türkdogan AK, Ersoy IH. Low high-density lipoprotein cholesterol is characterized by elevated oxidative stress. Angiology 2014;65:927–31.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JP, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109–22.
   PubMed Web of Science ®Google Scholar
• Schwartz GG1, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal- OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089–99.
   PubMed Web of Science ®Google Scholar
• Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004;95:858–66.
   PubMed Web of Science ®Google Scholar
• Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275–81.
   PubMed Web of Science ®Google Scholar
• Ni W, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, Inoue S. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001;103:2096–101.
   PubMed Web of Science ®Google Scholar
• Hoogeveen RC1, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005;183:301–7.
   PubMed Web of Science ®Google Scholar
• Navab M, Imes SS, Hama SY, Hough GP, Ross R, Bork W, Valente AJ, Berliner JA, Drinkwater DC, Laks H. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88:2039–46.
   PubMed Web of Science ®Google Scholar
• Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004;318:680–3.
   PubMed Web of Science ®Google Scholar
• Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51:314–24.
   PubMed Web of Science ®Google Scholar